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Abstract
Background: In recent years, some miRNAs have been reported to be connected closely with the development of 
human hepatocellular carcinoma. In our previous studies, a set of miRNAs were revealed to be dysregulated in HCC 
tissues. However, the functions of these miRNAs in HCC remain largely undefined.
Methods: The expression profiles of miR-183 were compared between HCC tissues and adjacent normal liver tissues 
using qRT-PCR method. This method was used to screen the potential target genes of miR-183. A luciferase reporter 
assay was conducted to confirm target association. Finally, the functional effect of miR-183 in hepatoma cells was 
examined.
Results: Among the 25 HCC samples analyzed, microRNA-183 was significantly up-regulated (twofold to 367-fold) in 
17 samples compared with the matching nontumoral liver tissues. Programmed cell death 4 (PDCD4) was identified as 
the target gene of miR-183. Moreover, PDCD4 is a proapoptotic molecule involved in TGF-β1-induced apoptosis in 
human HCC cells, we found that miR-183 transfectants were resistant to apoptosis induced by TGF-β1.
Conclusions: We conclude that miR-183 can inhibit apoptosis in human HCC cells by repressing the PDCD4 
expression, and miR-183 may play an important role in HCC development.
Background
Hepatocellular carcinoma (HCC) is a global health prob-
lem, with over 700,000 cases worldwide each year [1]. In
the USA alone, it is estimated that there will be over
20,000 new cases of primary liver cancers in 2008, with
the majority being HCC [2]. In china, HCC is the second
highest cancer killer since the 1990s, which alone
accounts for 53% of all liver cancer deaths worldwide [3].
Various molecular alterations occur in preneoplastic
nodules and escalate in HCC [4]. Several studies have
shown that specific miRNAs are aberrantly expressed in
malignant HCC cells or tissues compared to non-malig-
nant hepatocytes or tissue [5-8].
miRNAs have been discovered as naturally occurring
non-coding RNAs, controlling gene expression via spe-
cific sites at the 3'-UTR of target-mRNAs, causing trans-
lational repression or degradation [9,10]. Recent evidence
has shown that miRNA mutations or mis-expression cor-
relate with various human cancers and indicated that
miRNAs can function as tumour suppressors and onco-
genes. For example, let-7, downregulated in lung cancer,
suppresses Ras [11]. miR-15 and miR-16, deleted or
downregulated in leukemia [12], suppress BCL2 [13],
miR-17-5p and miR-20a control the balance of cell death
and proliferation driven by the proto-oncogene c-Myc
[14]. Many miRNAs such as miR-21, miR-224, miR-34a,
miR-221/222, miR-106a, and miR-203 are upregulated in
HCC compared to benign hepatocellular tumors such as
adenomas or focal nodular hyperplasia. Many other miR-
NAs have been noted to be decreased in HCC compared
to non-tumoral tissue, such as miR-122a, miR-422b, miR-
145, and miR-199a [5-8,15].
In this study, we compared the miR-183 expression pro-
file from HCC tumor tissues and adjacent normal liver
tissues. We found that miR-183 was up-regulated in HCC
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Page 2 of 10tumor tissues. Sequence analysis suggested a likely inter-
action between the 3'-UTR of PDCD4 mRNA and miR-
183. Therefore, we validated that miR-183 could repress
the expression of PDCD4 and analyzed its functions in
human HCC cells.
Methods
Patients and Tumor Characteristics
HCCs and surrounding control tissue specimens were
obtained from 25 patients at General Hospital of PLA
(Beijing, P.R. China) after surgical resection with
informed consent. The tumor tissues and adjacent nor-
mal tissues were frozen in liquid nitrogen after resection.
No patient in the current study received chemotherapy or
radiation therapy before the surgery. Liver samples were
fully clinically characterized (Table 1). This study was
performed with the approval of the Medical Ethical Com-
mittee of General Hospital of PLA.
Cell Lines and Cultures
HepG2 and Huh7 cell lines were grown in Dulbecco's
modified Eagle medium (DMEM) (GIBCO BRL, Grand
Island, NY) containing 10% fetal bovine serum (FBS) with
100 μg/ml penicillin/streptomycin at 37°C with 5% CO2.
Vector Construction
Wild-type 3'-untranslated region (3'-UTR) of PDCD4
containing predicted miR-183 target sites were amplified
by PCR from HepG2 cell genomic DNA. Primers used:
Forward: GAT CTG CAG AAG AAC TCT TGC AGT
CTT AGA; Reverse: GAT CAT ATG ATG TCA AGC
TTT GGG TCT CTG. Mutant 3'-UTRs were generated
by overlap-extension PCR method. Both wild-type and
mutant 3'-UTR fragments was subcloned into the pGL3-
control vector (Promega, Madison, WI) immediately
downstream of the stop codon of the luciferase gene, as
described before [16]. DNA fragment coding PDCD4
protein was amplified by PCR from HepG2 cell cDNA,
and cloned into pCMV-Myc expression vector
(Clonetech, Mountain View, CA). Primers used: Forward:
GCTG AAT TCG GAT GGA TGT AGA AAA TGA GCA
GA; Reverse: CTG CTC GAG TCA GTA GCT CTC TGG
TTT AAG A.
miRNAs, siRNAs and transfection
The miRNAs, siRNAs and miRNA inhibitor were synthe-
sized by GenePharma (Shanghai, China) (miR-183: 5'-
UAU GGC ACU GGU AGA AUU CAC UG-3'/5'-GUG
AAU UCU ACC AGU GCC AAA AU-3'; the si-PDCD4
target sequences were GUG UUG GCA GUA UCC UUA
G [17]; miR-183 inhibitor: 5'-AGU GAA UUC UAC CAG
UGC CAU A-3'). siRNAs and miRNAs transfections were
performed using Lipofectamine 2000 (Invitrogen, Carls-
bad, CA, USA). In brief, cells were plated in 6-well plate
to 40% confluence. For each well, 5 μl siRNA or miRNA
(20 μM) were added into 250 μl Opti-MEM medium, 3 μl
of Lipofectamine 2000 into 250 μl Opti-MEM medium
and then mixed siRNA or miRNA with Lipofectamine
2000. The mixture was added to cells and incubated for 6
h before replacing the medium. Total RNA and protein
were prepared 48 h after transfection and were used for
qRT-PCR or western blot analysis.
RNA extraction and qRT-PCR
Total RNA was extracted from the cultured cells using
Trizol Reagent (Invitrogen) according to the manufac-
turer's protocol. qRT-PCR was used to confirm the
expression levels of mRNAs and miRNAs. For mRNAs
detection, reverse transcription was performed according
to the protocol of Improm-II™ Reverse Transcriptase Sys-
tem (Promega); qPCR was performed as described in the
method of SYBR premix Ex Taq (TaKaRa, Dalian, China)
with Mx3000p (Stratagen, La Jolla, CA, USA) supplied
with analytical software. GAPDH mRNA levels were used
for normalization. For miRNAs detection, the qRT-PCR
was performed as described before [16]. One primer of
miRNAs amplification is miRNA specific, and the other
is a universal primer. U6 snRNA levels were used for nor-
malization. The oligonucleotides used as primers was:
PDCD4-F 5'-TGG ATT AAC TGT GCC AAC CA-3',
PDCD4-R 5'-TCT CAA ATG CCC TTT CAT CC-3';
G3PDH-F 5'-TCA GTG GTG GAC CTG ACC TG-3',
G3PDH-R 5'-TGC TGT AGC CAA ATT CGT TG-3';
miR-RT primer 5'-GCG AGC ACA GAA TTA ATA CGA
CTC ACT ATA GG(T)18VN-3'; miR-183 5'-TATG-
GCACTGG TAGAA TTC ACT-3'; universal primer 5'-
GCG AGC ACA GAA TTA ATA CGA C-3'; U6-F 5'-
CGC TTC GGC AGC ACA TAT ACT A-3', U6-R 5'-
CGC TTC ACG AAT TTG CGT GTC A-3'.
Western blot analysis
Protein extracts were prepared by a modified RIPA buffer
with 0.5% sodium dodecyl sulfate (SDS) in the presence
of proteinase inhibitor cocktail (Complete mini, Roche,
Indianapolis, IN, USA). Polyacrylamide gel electrophore-
sis, tank-based transfer to Immobilon Hybond-C mem-
branes (Amersham Biosciences) and immunodetection
were performed with standard techniques. Antibodies
against PDCD4 (12587-1-AP, ProteinTech, Chicago,
USA) and β-actin antibody (Zhongshan Biotechnology,
Beijing, China) were used in western analysis in accor-
dance with the manufacturer's instruction. Signals were
visualized with SuperSignal® West Pico chemolumines-
cent substrate (Pierce, Rockford, IL, USA) by exposure to
films.
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HepG2 cells were transfected in 24-well plates using
Lipofectamine 2000 transfection reagent. The transfec-
tion mixtures contained 100 ng of firefly luciferase
reporter plasmid and 5 pmol of miR-183 or 20 pmol of
miR-183 inhibitor. pRL-TK (Promega) was also trans-
fected as a normalization control. Cells were collected 48
h after transfection, and luciferase activity was measured
using a dual-luciferase reporter assay system (Promega).
Cell apoptosis
Huh7 Cells were transfected with miRNAs or siRNAs.
TGF-β1 (Sigma, st. Louis, MO, USA) was added 24 h
after transfection. 48 h after incubated, the cells were
Table 1: miR-183 and PDCD4 mRNA Expression Profiles in human hepatoma carcinoma tissues
Patient 
No.




HBsAg HCV-Ab Cirrhosis Normalized 
miR-183 Amount in 
Tumor Tissue 








1 35 F 5*4*4 3 Positive Negative Yes 32.90 0.37
2 52 M 8.5*7*6 2 Positive Negative No 16.68 0.41
3 43 M 3.5*3*2 2 Positive Negative Yes 6.36 0.89
4 41 F 12*10*8 3 Positive Negative No 3.39 0.32
5 34 M 10*7*7 3 Positive Negative Yes 4.96 0.41
6 50 M 2.5*2.5*2 3 Positive Negative No 23.59 0.74
7 33 M 10*8*7 4 Positive Negative Yes 0.33 1.45
8 50 M 2.5*1.8*1.5 1 Negative Negative No 0.53 0.34
9 52 M 10.5*8*5 3 Positive Negative Yes 2.08 0.4
10 52 M 10.5*8*5 3 Positive Negative Yes 9.06 0.92
11 63 M 14*10*10 2 Positive Negative Yes 1.29 1.25
12 70 M 3.5*3.5*3 2 Positive Negative Yes 25.28 0.08
13 66 F 15*7*5 3 Positive Negative No 48.84 0.31
14 39 M 12*11*6 3 Positive Negative No 5.94 0.50
15 51 M 2.5*2*2 2 Positive Negative Yes 101.83 0.35
16 47 M 5*5*4 2 Positive Negative Yes 0.28 0.98
17 37 M 16*4*8 2 Positive Negative Yes 367.09 0.21
18 52 M 8*7*4.5 2 Positive Negative No 0.39 1.57
19 64 M 8*5*4 2 Negative Positive No 0.17 6.19
20 50 F 6*5.5*2.5 1 Negative Negative No 130.69 0.2
21 52 M 7*7*7 3 Positive Negative Yes 1.38 0.23
22 56 M 8*6.5*5 3 Positive Negative Yes 0.88 0.47
23 48 M 2*2*1.5 2 Positive Negative No 48.17 0.17
24 59 M 8.8*8.5*8 2 Negative Negative No 41.93 0.26
25 40 M 2.5*2.5*2 2 Positive Negative Yes 16.34 0.41
HBsAg indicates hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; M, male; F, female; miRNA, microRNA. Relative quantification was 
performed by the 2-ΔΔCt method with adjacent normal liver tissue sample as a calibrator. Data show the means from three independent analyzes. 
Every independent analyze was carried out after the RNA extraction step. ΔCT obtained from real-time PCR was subject to paired t test. The 
expression levels of miR-183 in tumor tissues were significantly higher than in adjacent normal tissues (P < 0.01, t = - 3.07), and the expression 
levels of PDCD4 mRNA in tumor tissues were significantly lower than in adjacent normal tissues (P < 0.01, t = 3.69)
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Page 4 of 10fixed, stained with DAPI and analyzed for morphological
characteristics associated with apoptosis. Annexin-V
assays were performed using Annexin V-FITC kits pur-
chased from KeyGEN (Nanjing, china) according to man-
ufacturer's protocols. The data are expressed as the
percentage of apoptotic cells.
Statistical Analysis of Data
Unless stressed, all results are expressed as means ± SD.
Differences were assessed by two tailed Student t test
using Excel software. P < 0.05 was considered to be statis-
tically significant. Paired student's t-test was performed
to determine the difference of miRNA's expression levels
observed between non-cancerous and cancer tissues.
Results
miR-183 Is Upregulated in Human HCC
Expressions of miR-183 were examined further in an
independent series of primary HCC tumors and adjacent
nontumoral livers (The clinical parameter of the HCC
patients was shown in Table 1) by using Real-time PCR
method. The results shown that miR-183 was signifi-
cantly up-regulated (2 to 300 fold) in 68% of tumors (17 of
25 patients) compared to the matching adjacent nontu-
moral liver tissues (Table 1). These results suggest that
up-regulation of miR-183 may be involved in most of
human HCC development.
miR-183 represses the expression of PDCD4
To identify the functions of miR-183 in HCC cells, we
analyzed putative target genes by using the TargetScan
http://www.targetscan.org bioinformatics tools [18].
miR-183 maybe play the role of oncogene, considering it
is up-regulated in HCC. For this reason, three tumor sup-
pressor gene, such as death-associated protein (DAP),
programmed cell death 4 (PDCD4) and programmed cell
death 6 (PDCD6) were selected for further validation. To
identify the genuine targets, synthetic miR-183 and nega-
tive control RNA were transfected into hepatoma Huh7
cells. qRT-PCR was used to detect the expression levels of
those putative target genes. The results of qRT-PCR
showed that PDCD4 was down-regulated in Huh7 cells
transfected with miR-183, whereas the expression levels
of other two genes had no significant change (Fig. 1A).
Western blot analysis also showed that miR-183 mark-
edly reduced protein expression levels of PDCD4 com-
pared with negative control RNA and mock transfected
cells (Fig. 1B). All these results reveal that PDCD4 is reg-
ulated by miR-183.
To determine the clinical significance of miR-183 target
genes, we examined PDCD4 mRNA levels in 25 pairs of
matched HCC specimens by qRT-PCR. As expected in
Table 1, lower levels of PDCD4 were detected in 17 of 25
tumor tissues as compared with the non-tumor counter-
parts. Furthermore, PDCD4 mRNA levels were inversely
correlated with miR-183 expression (Fig. 1C), suggesting
that the decreased PDCD4 expression might result from
a high expression of miR-183 in HCC. However, we also
observed that miR-183 up-regulation in #3, 6, 10, 14 and
down-regulation in #8, 16 could not account for the
expression levels of PDCD4. These data suggest that miR-
183 might play a critical role on PDCD4 regulation in
over a half but not all of the HCC patients. These might
also represent the complexity of PDCD4 regulation espe-
cially in HCC. We speculate that other factors (either
protein or RNA) might antagonize or interferer the effect
of miR-183 on PDCD4, which needs further investiga-
tions.
Interaction of miR-183 with the 3'-UTR of the PDCD4 mRNA
Using bioinformatic analysis, we found that the putative
miR-183 binding site of PDCD4 3'-UTR was conserved
across various species (Fig. 2A). To determine whether
PDCD4 was direct targets of miR-183, the human
PDCD4 wild-type-3'-UTR containing the miR-183 bind-
ing site was cloned into a modified pGL-3 control vector.
In parallel, we constructed another reporter vector con-
taining the mutated PDCD4 3'-UTR sequence. These
luciferase reporter vectors were cotransfected into
HepG2 cells with negative control RNA or miR-183
respectively. The results of luciferase assays revealed that
miR-183 could act on wild type PDCD4 3'-UTR, and led
to a significant decrease of luciferase activity as compared
to control RNA (Fig. 2B). When the putative miR-183
binding site was mutated, there was no significant
decrease in relative luciferase activity compared with
control RNA (Fig. 2B). The corresponding results were
observed when the expression of miR-183 was repressed
by antisense RNA (Fig. 2C). These data suggest miR-183
may repress the expression of PDCD4 at posttranscrip-
tional level by targeting its 3'-UTRs. In other words,
PDCD4 is a direct target gene of miR-183.
miR-183 inhibits TGF-β1-induced apoptosis in Huh7 cells
PDCD4 is down-regulated in human HCC tissues com-
pared to corresponding non-tumoral liver tissues. Fur-
thermore, PDCD4 is involved in TGF-β1 induced
apoptotic signaling pathways in the HCC cell line Huh7
[19]. To investigate the function of miR-183 in HCC cells,
we transfected Huh7 cells with negative control RNA,
PDCD4 siRNA and miR-183 respectively, TGF-β1 was
added 24 h after transfection, and cells were further incu-
bated for 24 h. qRT-PCR and western blot results showed
that miR-183 and siRNA against PDCD4 led to in a sig-
nificant decrease of endogenous PDCD4 mRNA and pro-
tein levels compared to mock or negative control
transfection in Huh7 cells (Fig. 3A, C). At the same time,
we found that there were no significant changes in miR-
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cells treated with TGF-β1 (Fig. 3B).
PDCD4 is a proapoptotic molecule involved in TGF-
β1-induced apoptosis in human HCC cells [19], and miR-
183 can inhibit TGF-β1 induced PDCD4 expression in
Huh7 cells (Fig. 3A, C). Therefore, we wondered whether
miR-183 could influence apoptosis of Huh7 cells. To
eliminate the off-target effect of miR-183 on apoptosis,
we used siRNA to down-regulate PDCD4 gene expres-
sion. Both of DAPI staining of cells (Fig. 4A) and
Annexin-V assays (Fig. 4B) showed that the number of
apoptotic cells induced by TGF-β1 treatment was
reduced in the miR-183 and si-PDCD4 transfectants as
compared to the mock and negative control cells. To
finalize the function of miR-183-targeting these genes in
apoptosis regulation, rescue experiments were carried
out. Utilizing pCMV-Myc expression vector, PDCD4
construct without wild 3'-UTR was generated. As shown
in Fig. 4C, the inhibition effect of miR-183 on apoptosis
was rescued when PDCD4 expression vector was
cotransfected. These results indicated that miR-183 was
resistant to TGF-β1-induced apoptosis of Huh7 cells.
Discussion
In the current study, we show that miR-183 expression is
up-regulated in human HCC compared with matching
adjacent nontumoral tissue. We also show that PDCD4 is
negatively regulated by miR-183 at the posttranscrip-
tional level, via a specific target site within the 3'-UTR.
Moreover, we demonstrated that miR-183 was resistant
to TGF-β1-induced apoptosis of Huh7 cells, via repres-
sion of PDCD4 expression. These results support an
essential role of miR-183 in HCC development.
miR-183 is one member of miR-182-183 miRNA clus-
ter located in the 7q31-34 locus [20]. This miRNA cluster
including three miRNAs, i.e., miR-96, miR-182 and miR-
Figure 1 miR-183 inhibits the mRNA and protein expression of PDCD4. (A) HepG2 cells transfected with miR-183 compared with negative con-
trol transfected cells for 48 hours, the mRNA expression levels of three potential target genes were detected by qRT-PCR. (B) PDCD4 protein was de-
tected by western blot using anti-PDCD4 antibody and anti-β-actin antibody as a control. (C) Correlation between expression levels of miR-183 and 
PDCD4. U indicates up-regulation of miR-183 in HCC tissues, and NU indicates down-regulation and no significant change of miR-183 in HCC tissues. 
The mean value is shown as a horizontal line. Statistical analysis was performed with Student's t-test.
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sequences. Motoyama et al. have found an overexpression
of miR-183 in human colorectal cancer and Lin et al. have
reported that the miR-183-96-182 cluster was frequently
amplified in melanoma [21,22]. Here, we found that miR-
183 was resistant to TGF-β1-induced apoptosis in Huh7
cells, via repression of PDCD4 expression. Thus, it is
likely that miR-183 acts as an oncogene in a variety of
tumor types. However, miR-183 was identified as a
potential metastasis-inhibitor in lung cancer cells [23].
These data suggest that the effect of miR-183 as an onco-
gene is cell type dependent.
The programmed cell death 4 (PDCD4) was originally
identified as a tumor-related gene in humans and mapped
to chromosome10q24 [19,24]. PDCD4 protein is known
to bind eukaryotic initiation factor 4A (eIF4A), inhibit
translation initiation [25,26]. Moreover, PDCD4 has been
found to inhibit AP-1-mediated trans-activation and to
Figure 2 miR-183 can act on the 3'-UTR of PDCD4 directly. (A) The target site of miR-183 in PDCD4 3'UTR is conserved (shown in red) in many 
species. The PDCD4 3'-UTR mutant is identical to the wild-type, except that it has four point substitutions (red) disrupting pairing to miR-183 seed. (B) 
and (C) Luciferase assays indicated that miR-183 downregulated the expression of PDCD4 by targeting putative target site. NC RNA, miR-183, and miR-
183 inhibitor were cotransfected with a modified pGL-3 control vector containing wild-type PDCD4 3'-UTR or mutant, respectively.
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tor p21. As a result, loss of PDCD4 confers growth advan-
tages to the cells by several means and thereby facilitates
the development of cancer. PDCD4 expression is down-
regulated or lost in several tumor types [27]. However,
relatively little is known about mechanisms regulating
PDCD4 expression in cancer cells. Initial studies have
suggested that PDCD4 is regulated by topoisomerase-
inhibitors, COX-2-inhibitors, Myb and Akt [28]. In a
recent study, PDCD4 has been reported as a functional
Figure 3 miR-183 inhibits TGF-β1-induced PDCD4 expression in Huh7 cells. Cells were transfected with NC RNA, siPDCD4, or miR-183 respec-
tively, after 24 hours, TGF-β1 (5 ng/mL) was added. Cells were harvested 24 hours later, and were subsequently processed for qRT-PCR (A) and Western 
blot (C) analysis by hybridization with antibodies against PDCD4 and β-actin. At the same time, the effect of TGF-β1 on miR-183 was examined (B). 
Huh7 cells were treated with TGF-β1 (5 ng/mL) for 48 h, then harvested and processed for qRT-PCR analysis.
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Figure 4 miR-183 transfectants were resistant to apoptosis induced by TGF-β1. (A) DAPI assay. Huh7 cells were transfected with NC RNA, 
siPDCD4, or miR-183 respectively, after 24 hours, TGF-β1 (5 ng/mL) was added. Cells were further incubated for 48 hours, fixed, and stained with DAPI. 
*P < 0.05 compared with Huh7 cells transfected with NC RNA. (B) Annexin-V assays. Huh7 cells were transfected and cultured as described in (A), then 
collected by trypsinization followed by centrifugation and stained with FITC conjugated Annexin-V and PI. (C) miR-183 and PDCD4 expression vector 
were cotransfected into Huh7 cells, after 24 hours, TGF-β1 (5 ng/mL) was added. Cells were further incubated for 48 hours, fixed, and stained with 
DAPI. * P < 0.05 compared with Huh7 cells transfected with control pCMV vector.
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cell proliferation, invasion, metastasis, and neoplastic
transformation in breast cancer [27,29,30], invasion,
intravasation, and metastasis in colon cancer [28], prolif-
eration and invasion in esophageal squamous cell carci-
noma [31]. Here, we found that PDCD4 was negatively
regulated by miR-183 in HCC cells. All these data suggest
the regulation mechanism of PDCD4 is very complex,
many factors (either protein or RNA) might influence the
expression of PDCD4.
Conclusions
This study suggests that miR-183, up-regulated in HCC,
represses the expression of the tumor-suppressor PDCD4
posttranscriptionally, and inhibits TGF-β1-induced
apoptosis in human HCC cells. Therefore, miR-183 may
play an important role in HCC development.
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